Antibe Therapeutics Inc (ATE):企業の財務・戦略的SWOT分析

◆英語タイトル:Antibe Therapeutics Inc (ATE) - Financial and Strategic SWOT Analysis Review
◆商品コード:DATA904C15089
◆発行会社(調査会社):GlobalData
◆発行日:2019年3月
◆ページ数:25
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:カナダ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD300 ⇒換算¥33,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD600 ⇒換算¥66,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD900 ⇒換算¥99,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Antibe Therapeutics Inc (Antibe) is a biotech company that designs and develops drug candidates for chronic pain and inflammation; and regenerative medicine. The company discovers and commercializes novel drugs, biologics and medical devices. It offers lead compound ATB-346, a naproxen derivative for osteoarthritis, rheumatoid arthritis and ankylosing spondylitis; ATB-352 for gout, dental pain, post-surgical pain, and ATB-340 for chronic prevention of cardiovascular disease and cancer chemoprevention. Antibe also offers regenerative medical devices such as CGX-227, CGX-443 and CGX-276 which are indicated for oral and maxillofacial surgery. The company markets its products in Canada and abroad. Antibe is headquartered in Toronto, Ontario, Canada.

Antibe Therapeutics Inc Key Recent Developments

Nov 30,2018: Antibe Therapeutics to present at the 11th Annual LD Micro Main Event on December 4, 2018
Nov 23,2018: Antibe Therapeutics reports Q2 2019 interim financial and operating results
Oct 22,2018: Antibe Therapeutics establishes business development Advisory Board
Oct 10,2018: Antibe Therapeutics Receives Approval to Initiate Part One of Phase 2B Dose-Ranging, Efficacy Study for ATB-346
Oct 03,2018: Antibe Therapeutics Announces Grant of Restricted Share Units

This comprehensive SWOT profile of Antibe Therapeutics Inc provides you an in-depth strategic analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

This company report forms part of GlobalData’s ‘Profile on Demand’ service, covering over 50,000 of the world’s leading companies. Once purchased, GlobalData’s highly qualified team of company analysts will comprehensively research and author a full financial and strategic analysis of Antibe Therapeutics Inc including a detailed SWOT analysis, and deliver this direct to you in pdf format within two business days. (excluding weekends).

The profile contains critical company information including*,

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Note*: Some sections may be missing if data is unavailable for the company.

Key benefits of buying this profile include,

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

【レポートの目次】

Table of Contents

Section 1 – About the Company

Antibe Therapeutics Inc – Key Information
Antibe Therapeutics Inc – Overview
Antibe Therapeutics Inc – Key Employees
Antibe Therapeutics Inc – Key Employee Biographies
Antibe Therapeutics Inc – Key Operational Heads
Antibe Therapeutics Inc – Major Products and Services
Antibe Therapeutics Inc – History
Antibe Therapeutics Inc – Company Statement
Antibe Therapeutics Inc – Locations And Subsidiaries
Antibe Therapeutics Inc – Key Manufacturing facilities
Head Office
Other Locations & Subsidiaries

Section 2 – Company Analysis

Antibe Therapeutics Inc – Business Description
Antibe Therapeutics Inc – Corporate Strategy
Antibe Therapeutics Inc – SWOT Analysis
SWOT Analysis – Overview
Antibe Therapeutics Inc – Strengths
Antibe Therapeutics Inc – Weaknesses
Antibe Therapeutics Inc – Opportunities
Antibe Therapeutics Inc – Threats
Antibe Therapeutics Inc – Key Competitors

Section 3 – Company Financial Performance Charts

Antibe Therapeutics Inc – Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts

Section 4 – Appendix

Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

Note*: Some sections may be missing if data is unavailable for the company

List of Tables

Antibe Therapeutics Inc, Key Information
Antibe Therapeutics Inc, Key Ratios
Antibe Therapeutics Inc, Share Data
Antibe Therapeutics Inc, Major Products and Services
Antibe Therapeutics Inc, History
Antibe Therapeutics Inc, Key Employees
Antibe Therapeutics Inc, Key Employee Biographies
Antibe Therapeutics Inc, Key Operational Heads
Antibe Therapeutics Inc, Other Locations
Antibe Therapeutics Inc, Subsidiaries
Antibe Therapeutics Inc, Key Manufacturing facilities
Antibe Therapeutics Inc, Key Competitors
Antibe Therapeutics Inc, SWOT Analysis
Antibe Therapeutics Inc, Ratios based on current share price
Antibe Therapeutics Inc, Annual Ratios
Antibe Therapeutics Inc, Interim Ratios
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures

Antibe Therapeutics Inc, Performance Chart
Antibe Therapeutics Inc, Ratio Charts

★海外企業調査レポート[Antibe Therapeutics Inc (ATE):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Phoenix Pharmahandel GmbH & Co KG:企業の戦略的SWOT分析
    Phoenix Pharmahandel GmbH & Co KG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major p …
  • Dometic Group AB:企業の戦略・SWOT・財務情報
    Dometic Group AB - Strategy, SWOT and Corporate Finance Report Summary Dometic Group AB - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Servair:企業の戦略・SWOT・財務情報
    Servair - Strategy, SWOT and Corporate Finance Report Summary Servair - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, pr …
  • Lekoil Ltd (LEK):企業の財務・戦略的SWOT分析
    Summary Lekoil Ltd (Lekoil) is an oil and gas exploration and production company with interests in Nigeria and Namibia. The company owns oil and gas exploration and production properties such as Otakikpo marginal field, Nigeria Dahomey Basin OPL310 and Nigeria Dahomey Basin OPL 325 in Nigeria, and B …
  • CIMIC Group Ltd (CIM):企業の財務・戦略的SWOT分析
    CIMIC Group Ltd (CIM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Infineon Technologies AG:企業の戦略・SWOT・財務情報
    Infineon Technologies AG - Strategy, SWOT and Corporate Finance Report Summary Infineon Technologies AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Cellink AB (CLNK B):企業の財務・戦略的SWOT分析
    Cellink AB (CLNK B) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • nLife Therapeutics SL:製薬・医療:M&Aディール及び事業提携情報
    Summary nLife Therapeutics SL (nLife Therapeutics) is a biopharmaceutical company that discovers and develops cell specific oligonucleotides as therapeutic agents for the treatment of central nervous system and neuromuscular disorders. The company’s lead candidate includes NLF-PD-1233, an oligonucle …
  • Caixa Economica Federal
    Caixa Economica Federal - Strategy, SWOT and Corporate Finance Report Summary Caixa Economica Federal - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Raya Holding (RAYA):企業の財務・戦略的SWOT分析
    Raya Holding (RAYA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • New Gold Inc.:企業のM&A・事業提携・投資動向
    New Gold Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's New Gold Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments …
  • Weifa ASA (WEIFA)-製薬・医療分野:企業M&A・提携分析
    Summary Weifa ASA (Weifa), formerly Aqualis ASA, is a pharmaceutical company that conducts the research and development, manufacture, distribution and sales of pharmaceutical products, lifestyle products and solutions. The company has over the counter (OTC) pharmaceutical market in Norway offering p …
  • Alma Media Corporation:企業のM&A・事業提携・投資動向
    Alma Media Corporation - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Alma Media Corporation Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions …
  • Fluor Corp (FLR):電力:M&Aディール及び事業提携情報
    Summary Fluor Corp (Fluor) is a provider of engineering and construction services. The company's service portfolio includes design, engineering, procurement, fabrication, modularization, construction, commissioning and maintenance, and project management solutions. Fluor also offers other services t …
  • Personal Genome Diagnostics Inc:製品パイプライン分析
    Summary Personal Genome Diagnostics Inc (PGD) is a genomic solution provider. The company develops next-generation sequencing and proprietary algorithms to identify alterations in complex cancer genomes. It provides a portfolio of regulated tissue-based and liquid biopsy genomic products for laborat …
  • Taconic Biosciences Inc:医療機器:M&Aディール及び事業提携情報
    Summary Taconic Biosciences Inc (Taconic), formerly Taconic Farms Inc is a research model provider that offers animal health models and laboratory services. The company’s products include taconic transgenic mouse models, emerging models, cryopreserved models, traditional models, diet induced obese, …
  • Orbis S.A.:戦略・SWOT・企業財務分析
    Orbis S.A. - Strategy, SWOT and Corporate Finance Report Summary Orbis S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Etihad Airways:企業のM&A・事業提携・投資動向
    Etihad Airways - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Etihad Airways Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestmen …
  • Lightstream Resources Ltd. (LTS)-石油・ガス分野:企業M&A・提携分析
    Summary Lightstream Resources Ltd. (Lightstream) is an upstream energy company that carries out the acquisition, exploration, development and production of oil and natural gas reserves with a focus on light oil. Its main operating areas include the Bakken and Mississippian formations, Cardium format …
  • BiondVax Pharmaceuticals Ltd (BVXV):企業の財務・戦略的SWOT分析
    Summary BiondVax Pharmaceuticals Ltd (BiondVax Pharmaceuticals) is a biopharmaceutical company that develops universal flu vaccine. The company provides lead product M-001 is a synthetic peptide-based protein that offers protection against human influenza virus strains including seasonal influenza s …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆